Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

20263 citationsJournal Article

Authors

Lana A. Castellucci · University of Ottawa

Vivien Chen · The University of Sydney

Michael J. Kovacs · Western University

Alejandro Lazo-langner · Western University

Peter Greenstreet · Ottawa Hospital

SR Kahn · Jewish General Hospital

Benoît Côté ·

Abstract

Among patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. (Funded by the Canadian Institutes of Health Research and others; COBRRA ClinicalTrials.gov number, NCT03266783.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 11, pp. 1051-1060

DOI: 10.1056/nejmoa2510703

Field-Weighted Citation Impact: 87.24